Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

v3.19.2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Current assets    
Cash and cash equivalents $ 34,574 $ 68,379
Marketable securities - available-for-sale debt securities 98,832 136,755
Accounts receivable, net of allowance for doubtful accounts of $0 and $0 3,809 192
Other current assets and prepaid expenses (including current portion of clinical materials) 37,918 25,769
Total current assets 175,133 231,095
Restricted cash 4,403 4,097
Clinical materials 2,690 3,953
Operating lease right-of-use assets, net of accumulated amortization 21,507  
Property, plant and equipment, net of accumulated depreciation of $19,528 (2018: $15,924) 33,722 36,118
Intangibles, net of accumulated amortization 2,066 1,473
Total assets 239,521 276,736
Current liabilities    
Accounts payable 4,344 4,083
Operating lease liabilities, current 2,338  
Accrued expenses and other accrued liabilities 18,595 20,354
Deferred revenue 3,016  
Total current liabilities 28,293 24,437
Operating lease liabilities, non-current 23,666  
Other liabilities, non-current 571 5,414
Total liabilities 52,530 29,851
Stockholders' equity    
Common stock - Ordinary shares par value ?0.001, 785,857,300 authorized and 630,672,578 issued and outstanding (2018: 701,103,126 authorized and 627,454,270 issued and outstanding) 943 939
Additional paid in capital 581,245 574,208
Accumulated other comprehensive loss (8,199) (9,763)
Accumulated deficit (386,998) (318,499)
Total stockholders' equity 186,991 246,885
Total liabilities and stockholders' equity $ 239,521 $ 276,736